Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders on May 15, 2025 Capital Carlyle contingent value right CVR DKK1 gene Family Turdidae (organism) merger private equity shareholders upfront cash +
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird on April 16, 2025 Ayrmid Capital deadline Failed Family Turdidae (organism) gene therapy private equity proposal - intent United States Food and Drug Administration +
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer on March 31, 2025 Ayrmid Bluebird Bio Capital Carlyle Family Turdidae (organism) gene therapy High Twice a day +
Bluebird Bio's Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation on February 24, 2025 Acquisition Capital Carlyle DKK1 gene Family Turdidae (organism) Financial Stress gene therapy Industry private equity +